In vitro Assays and analytics
for Precision Medicine
in Hematological Malignancies
an expert company devoted to
especially to Multiple Myeloma.
Diag2Tec is an expert company devoted to hematological cancers, especially to Multiple Myeloma (MM).
Diag2Tec offers to pharmaceutical and biotechnology companies the in vitro assessment of drug efficiency, characterization of mechanism of action and identification of predictive biomarkers of drug response.
Diag2Tec offers to oncologists, to improve diagnosis and treatment strategies to develop precision medicine in hematological malignancies.
Assessment of drug efficiency and characterization of mechanism of action
Identification of a personalized therapeutic treatment for each patient “Chemoresponse assays”
Development of biomarkers and companion diagnostics to deliver precision medicine